How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
British Journal of Pharmacology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 13, 2025
Obesity
is
a
complex
and
growing
global
concern,
affecting
one
in
eight
individuals
compromising
health,
quality
of
life
expectancy.
It
carries
significant
metabolic,
cardiovascular,
oncological,
hepatorenal,
skeletal
psychiatric
risks,
imposing
substantial
costs
on
health‐care
systems.
Traditional
treatments
have
often
been
ineffective
or
led
to
relapse
after
lifestyle
changes.
Whereas
bariatric
surgery
effective,
it
also
involves
risks
such
as
mortality
hospitalisation.
Semaglutide,
licensed
2018,
synthetic
analogue
glucagon‐like
peptide
1
which
regulates
glucose
metabolism
gastrointestinal
(GI)
motility.
Studies
show
that
semaglutide,
administered
either
weekly
subcutaneously,
daily
orally,
induces
an
average
weight
loss
−11.62
kg
compared
placebo
reduces
waist
circumference
by
up
−9.4
cm.
improves
blood
pressure,
fasting
levels,
C‐reactive
protein
levels
lipid
profiles.
The
most
common
adverse
events
are
mild‐to‐moderate
GI
complaints
occurring
more
frequently
with
administration
than
doses;
hypoglycaemia
without
intervention.
Weight
regain
follows
semaglutide
withdrawal.
Furthermore,
offers
cardiovascular
benefits
for
patients
established
atherosclerotic
disease
(CVD),
lowers
the
risk
kidney
outcomes
cardiovascular‐related
death,
resolves
nonalcoholic
steatohepatitis
many
cases,
positively
impacts
mental
health
life.
In
conclusion,
therapy
could
significantly
benefit
adults
regarding
CVD
if
made
widely
accessible.
Ethical
financial
considerations
must
be
addressed
personalised
obesity
treatment
approaches.
Language: Английский
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review
Candace Jarade,
No information about this author
Tetiana Zolotarova,
No information about this author
Areesha Moiz
No information about this author
et al.
EClinicalMedicine,
Journal Year:
2024,
Volume and Issue:
75, P. 102789 - 102789
Published: Aug. 15, 2024
Language: Английский
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador,
No information about this author
Carla Moutinho,
No information about this author
Carla Silva
No information about this author
et al.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(3), P. 399 - 399
Published: March 12, 2025
This
review
addresses
the
role
of
semaglutide
(SMG),
a
GLP-1
receptor
agonist,
in
treatment
obesity
and
its
related
comorbidities.
Originally
developed
for
type
2
diabetes
(DM2),
SMG
has
shown
significant
efficacy
weight
reduction,
with
superior
results
compared
to
other
treatments
same
class.
Its
effects
include
appetite
suppression,
increased
satiety,
improvements
cardiovascular,
renal,
metabolic
parameters.
Studies
such
as
SUSTAIN,
PIONEER,
STEP
highlight
superiority
agonists
anti-obesity
drugs.
The
oral
formulation
showed
promising
initial
results,
higher
doses
(50
mg)
showing
losses
comparable
those
subcutaneous
administration.
Despite
benefits,
there
are
challenges,
regain
after
cessation
treatment,
gastrointestinal
adverse
effects,
variability
response.
Future
studies
should
explore
strategies
mitigate
these
identify
predictive
factors
efficacy,
expand
therapeutic
indications
conditions
insulin
resistance.
constant
innovation
this
class
drugs
reinforces
potential
transform
protocols
chronic
weight-related
diseases.
Language: Английский
Application of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies
Meditsinskiy sovet = Medical Council,
Journal Year:
2024,
Volume and Issue:
16, P. 246 - 255
Published: Nov. 1, 2024
Introduction
.
Semaglutide
preparations
are
an
important
therapeutic
option
for
patients
suffering
from
type
2
diabetes
mellitus
and
obesity
due
to
their
high
efficacy
the
expected
increase
in
prevalence
of
these
diseases.
Consequently,
there
is
a
growing
need
development
domestic
analogs
semaglutide
requiring
bioequivalence
studies.
This
study
proposes
use
high-performance
liquid
chromatography
with
tandem
mass
spectrometry
(HPLC-MS/MS)
as
alternative
widely
used
immunoassay
quantitative
determination
human
serum.
Aim
To
develop
validate
method
serum
using
HPLC-MS/MS.
Materials
methods
Serum
sample
preparation
was
based
on
protein
precipitation
acetonitrile-methanol
mixture.
Liraglutide
selected
internal
standard.
The
mobile
phase
consisted
0.3%
formic
acid
water
acetonitrile.
stationary
represented
by
Phenomenex
Kinetex
C18
chromatographic
column
100×3.0
mm,
5
μm,
100
Å.
Ionization
liraglutide
performed
positive
electrospray
mode.
Detection
carried
out
multiple
reaction
monitoring
mode
(MRM).
Results
demonstrated
accuracy
precision,
relative
error
standard
deviation
values
less
than
15%
across
all
quality
control
levels.
confirmed
analytical
ranges
were
0.50–200.00
ng/mL
1.00–800.00
ng/mL.
Over
3.400
volunteer
samples
analyzed
part
Compared
ELISA
method,
proposed
provides
higher
selectivity
reproducibility
measurements.
Conclusions
has
been
developed
that
reproducible
blood
validated
accordance
EAEU
requirements
successfully
applied
studies
GP40331
(GEROPHARM
LLC,
Russia).
suitable
conducting
pharmacokinetic
other
preparations.
Language: Английский